CHEK2 and prostate carcinoma: A similar mechanism has been previously suggested for prostate cancer, since patients with pathogenic germline CHEK2 mutations displayed a significantly higher prevalence of the somatic CDK12 mutation than unselected prostate cancer patients from the TCGA cohort.